Your browser doesn't support javascript.
Application of estimand framework in ICH E9 (R1) to safety evaluation.
Wang, Xuelong; Yang, Ping; Yuan, Shuai S; Wang, William W B.
  • Wang X; BARDS, Merck & Co, Rahway, New Jersey, USA.
  • Yang P; BARDS, MSD China Holding Co, Ltd, Shanghai, China.
  • Yuan SS; Oncology Statistics, GSK, Collegeville, Pennsylvania, USA.
  • Wang WWB; BARDS, Merck & Co, Rahway, New Jersey, USA.
J Biopharm Stat ; 33(4): 476-487, 2023 Jul 04.
Article in English | MEDLINE | ID: covidwho-2286214
ABSTRACT
Defining the right question of interest is important to a clinical study. ICH E9 (R1) introduces the framework of an estimand and its five attributes, which provide a basis for connecting different components of a study with its clinical questions. Most of the applications of the estimand framework focus on efficacy instead of safety assessment. In this paper, we expand the estimand framework into the safety evaluation and compare/contrast the similarity and differences between safety and efficacy estimand. Furthermore, we present and discuss applications of a safety estimand to oncology trials and pooled data analyses. At last, we also discuss the potential usage of safety estimand to handle the impacts of COVID-19 pandemic on safety assessment.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Neoplasms Type of study: Experimental Studies / Prognostic study Limits: Humans Language: English Journal: J Biopharm Stat Journal subject: Pharmacology Year: 2023 Document Type: Article Affiliation country: 10543406.2023.2189452

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Neoplasms Type of study: Experimental Studies / Prognostic study Limits: Humans Language: English Journal: J Biopharm Stat Journal subject: Pharmacology Year: 2023 Document Type: Article Affiliation country: 10543406.2023.2189452